Abstract: The invention relates to a method for diagnosis of a disease, wherein presence or absence of an anti-endothelin-receptor antibody is determined in a sample from a patient to be diagnosed more in particular an anti-endothelin-receptor-A antibody. The disease according to the invention is in particular selected from diabetes, preferably type I diabetes, graft rejection, pre-eclampsia, hypertension, vasculitis, collagenosis, Raynaud-Syndrom (Morbus Raynaud), and inflammatory rheumatic disease and arteriosclerosis. The invention further relates to the use of an inhibitor of an anti-endothelin-receptor antibody or an inhibitor of an endothelin-receptor for the production of a medicament as well as a method for removing anti-endothelin-receptor antibodies from isolated blood by means of plasmapheresis.

Abstract: A method for diagnosis and/or prediction of hypertension and/or cardiovascular end-organ damage is disclosed. The method disclosed comprises the determination of the presence of soluble pro-renin receptor in samples derived from a subject. Furthermore, the use of anti-sPRR antibodies in diagnosis and/or prediction of cardiovascular end-organ damage is encompassed.

Abstract: The present invention relates to a method for diagnosis of a disease selected from the group of diabetes, vasculitis, collagenosis, an inflammatory rheumatic disease and arteriosclerosis wherein, presence or absence of an anti-AT1-receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease. The invention further relates to the use of an inhibitor of an anti-AT1-receptor antibody or an inhibitor of an AT1-receptor for the production of a medicament as well as plasmapheresis of blood for the removal of anti-AT1-receptor antibodies.

Abstract: The invention relates to a method for diagnosis of multiple sclerosis (MS) wherein, presence or absence of an anti-AT1 receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease.

Abstract: The invention relates to a method and an immunological test kit for predicting the risk of transplant rejection by detecting anti-AT1 receptor auto-antibodies in biological materials of a patient to be examined, e.g. by an immune reaction with the AT1 receptor or functionally analogous peptides or proteins thereof. The invention is also directed to the use of the AT1 receptor or functionally analogous peptides or proteins in order to predict (diagnose) the risk of transplant rejection. Said risk exists if anti-AT1 receptor auto-antibodies can be detected in such biological materials, e.g. in body fluids or tissues.

Abstract: The present invention relates to a method for diagnosis of a disease selected from the group of diabetes, vasculitis, collagenosis, an inflammatory rheumatic disease and arteriosclerosis wherein, presence or absence of an anti-AT1-receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease. The invention further relates to the use of an inhibitor of an anti-AT1-receptor antibody or an inhibitor of an AT1-receptor for the production of a medicament as well as plasmapheresis of blood for the removal of anti-AT1-receptor antibodies.

Abstract: The invention relates to a method for diagnosis of a disease, wherein presence or absence of an anti-endothelin-receptor antibody is determined in a sample from a patient to be diagnosed more in particular an anti-endothelin-receptor-A antibody. The disease according to the invention is in particular selected from diabetes, preferably type I diabetes, graft rejection, pre-eclampsia, hypertension, vasculitis, collagenosis, Raynaud-Syndrom (Morbus Raynaud), and inflammatory rheumatic disease and arteriosclerosis. The invention further relates to the use of an inhibitor of an anti-endothelin-receptor antibody or an inhibitor of an endothelin-receptor for the production of a medicament as well as a method for removing anti-endothelin-receptor antibodies from isolated blood by means of plasmapheresis.

Abstract: The invention relates to a method and an immunological test kit for predicting the risk of transplant rejection by detecting anti-AT1 receptor auto-antibodies in biological materials of a patient to be examined, e.g. by an immune reaction with the AT1 receptor or functionally analogous peptides or proteins thereof. The invention is also directed to the use of the AT1 receptor or functionally analogous peptides or proteins in order to predict (diagnose) the risk of transplant rejection. Said risk exists if anti-AT1 receptor auto-antibodies can be detected in such biological materials, e.g. in body fluids or tissues.